

**GIOVEDI, 31 MARZO 2022**

ore 16:30

<https://unito.webex.com/unito-en/j.php?MTID=m03d6be35a03b85f0c85cecc4b677245d>

***Daniel POULIQUEN***

*Université d'Angers, Inserm, Centre de Recherche en Cancérologie et Immunologie (CRCINA), Nantes*

**Experimental models of malignant mesothelioma, contribution of proteomics analyses and evaluation of the therapeutic efficacy of curcumin.**

Daniel Loïc Pouliquen, born March 17, 1960, obtained a pharmacist degree together with a specialized degree (CES) in Clinical Biochemistry in Rennes, France, in 1984. After a PhD in Biological Sciences and Health (Rennes I University, 1988), he developed the characterization and applications of new NMR contrast agents for proton MRI, and taught Biophysics as assistant professor at the School of Medicine in Angers, France. Following a postdoctoral fellowship at the Department of Radiology of the Massachusetts General Hospital, Boston, USA (Pr D. D. Stark), he became staff researcher (CR1) of the French National Institute of Health (Inserm) in December 1991, working on the design and applications of superparamagnetic iron oxide nanoparticles (SPIO) in MRI. From 1995 to 2001, he extended the scope of proton NMR relaxometry to the study of water states and dynamic properties in normal and tumor tissues, organisms under development (seeds, fish eggs and embryos), and biological fluids. These studies provided some insights in the biophysics of water in tissues during carcinogenesis. He further explored the quantitative and qualitative changes of the different water phases in mitochondria and pointed to some beneficial effects of a phytochemical-enriched diet in the prevention of some experimental models of cancers in mice and rats (myeloma, glioblastoma) in Angers (Inserm EMI00/18) and then in Nantes (Inserm U419 and UMR 601) (2001 to 2008). From 2008 to 2018, he established a biocollection of preneoplastic and neoplastic cell lines and experimental models of malignant mesothelioma (MM) for basic research on the biology of this aggressive cancer and evaluation of new strategies of treatment (Inserm UMR 892 and UMR 1232 (team 4, CRCINA, Nantes)). Since 2019, he works on the identification of new biomarkers of cancer invasiveness by quantitative proteomics (SWATH-MS), using cell lines, experimental MM tumors and formalin-fixed paraffin-embedded sections of tumors and surrounding tissues (team 3, CRCl<sub>2</sub>NA, ICO Cancer Center, Angers).